STOCK TITAN

Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Mineralys Therapeutics (NASDAQ: MLYS) announced its plan to release financial results for the fourth quarter ending December 31, 2022, on March 15, 2023, post-market close. A conference call with management is scheduled for 4:30 p.m. ET on the same day, accessible via 1-877-704-4453 (U.S.) or 1-201-389-0920 (international) with conference ID 13736564. The company is focused on developing treatments for diseases linked to high aldosterone levels, with its lead candidate, lorundrostat, targeting uncontrolled hypertension.

Positive
  • None.
Negative
  • None.

RADNOR, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter ended December 31, 2022, after the financial markets close on Wednesday, March 15, 2023.

The Company’s management team will host a conference call at 4:30 p.m. ET on Wednesday, March 15, 2023. To access the call, please dial 1-877-704-4453 in the U.S. or 1-201-389-0920 outside the U.S., followed by the conference ID: 13736564. A live webcast of the conference call may be found here. A replay of the call will be available on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

Wednesday, March 15 @ 4:30 p.m. ET
Domestic: 1-877-704-4453
International: 1-201-389-0920
Conference ID: 13736564
Webcast: Link

About Mineralys

Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its primary product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension.

Mineralys is based in Radnor, Pennsylvania. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn.

Contact:

investorrelations@mineralystx.com

 


FAQ

When will Mineralys report its financial results?

Mineralys will report its financial results on March 15, 2023.

What time is the Mineralys conference call?

The conference call is scheduled for 4:30 p.m. ET on March 15, 2023.

How can I access the Mineralys conference call?

You can access the call by dialing 1-877-704-4453 in the U.S. or 1-201-389-0920 internationally.

What is the main focus of Mineralys Therapeutics?

Mineralys focuses on developing treatments for diseases driven by elevated aldosterone levels.

What is the primary product candidate of Mineralys?

The primary product candidate is lorundrostat, targeting uncontrolled hypertension.

Mineralys Therapeutics, Inc.

NASDAQ:MLYS

MLYS Rankings

MLYS Latest News

MLYS Stock Data

666.34M
49.73M
2.55%
100.62%
3.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
RADNOR